Oksa A, Fedelesová V, Spustová V, Dzúrik R
Ustav preventívnej a klinickej medicíny-klinika farmakoterapie, Bratislava.
Vnitr Lek. 1998 Feb;44(2):63-7.
The authors investigated in 18 patients with essential hypertension the action of celiprolol (usually in combination with a diuretic) on the glucose and lipid metabolism in an open three-month trial. They evaluated the glucose, insulin and C-peptide concentration during an oral glucose tolerance test (oGTT) and the serum lipid concentration before and after treatment. It was revealed: 1. There are no significant changes in the glucose, insulin and C-peptide concentrations on fasting, 2. There is a significant reduction of the blood sugar level during the second hour of oGTT after treatment, 3. A significant reduction of glucose and C-peptide during the 1st and 2nd hour of oGTT after treatment in the sub-group with a poor glucose tolerance/insulin sensitivity, 4. There are no differences between the mentioned variables in hypertonic patients with a normal glucose metabolism, 5. There are no significant changes in values of total cholesterol, HDL-, LDL and VLDL-cholesterol and triacylglycerols. Celiprolol can exert in combination with diuretics also a favourable effect on the glucose tolerance/insulin sensitivity in patients with essential hypertension and metabolic syndrome.
作者在一项为期三个月的开放性试验中,研究了18例原发性高血压患者服用塞利洛尔(通常与利尿剂联用)对糖脂代谢的影响。他们在口服葡萄糖耐量试验(oGTT)期间评估了血糖、胰岛素和C肽浓度,并在治疗前后评估了血脂浓度。结果显示:1. 空腹时血糖、胰岛素和C肽浓度无显著变化;2. 治疗后oGTT第二小时血糖水平显著降低;3. 在糖耐量/胰岛素敏感性较差的亚组中,治疗后oGTT第一小时和第二小时血糖和C肽显著降低;4. 糖代谢正常的高血压患者上述变量无差异;5. 总胆固醇、高密度脂蛋白、低密度脂蛋白和极低密度脂蛋白胆固醇以及三酰甘油的值无显著变化。塞利洛尔与利尿剂联用对原发性高血压和代谢综合征患者的糖耐量/胰岛素敏感性也有有益作用。